You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: metformin used alone or combined with clomifene may improve ovulation rates in the polycystic ovary syndrome

https://doi.org/10.1136/ebm.9.3.85

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951–6.
    OpenUrlAbstract/FREE Full Text

    


    Lord JM, Flight IH, Norman RJ Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome Cochrane Database Syst Rev 2003;(3):CD003053.

    
 
 Q In women with the polycystic ovary syndrome (PCOS), what is the effectiveness of insulin sensitising drugs?

    GP/FP/Primary care ★★★★★☆☆ Gynaecology ★★★★★★☆ Endocrine ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    the Cochrane Menstrual Disorders and Subfertility Group trials register (December 2002), the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2002), Medline (1966 to December 2002), and EMBASE/Excerpta Medica (1985 to December 2002); bibliographies of relevant studies; and pharmaceutical companies.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) that compared insulin sensitising drugs with placebo, no treatment, or an ovulation inducting agent in women with PCOS based on biochemical or ultrasonographic evidence. Studies were assessed for allocation concealment, blinding, loss to follow up, non-compliance, and intention to treat analysis.

    Embedded ImageOutcomes:

    clinical (including live birth rate, clinical pregnancy rate, spontaneous ovulation, menstrual cyclicity, and adverse …

    View Full Text

    Footnotes

    • For correspondence: Dr J M Lord, Derriford Hospital, Plymouth, UK. jonathan_lordhotmail.com

    • Source of funding: Reproductive Medicine Unit, University of Adelaide.